LNAI
Lunai Bioworks Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.47
−30.63%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +98.2%
- EBIT
- +88.1%
- EPS
- +98.7%
- Free cash flow
- +32.8%
- Operating cash flow
- +32.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +95.6%
- EBIT
- +57.6%
- Net income
- +98.0%
- EPS
- +98.8%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026